- Home
- NMCO vs ABUS Comparison
NMCO vs ABUS Comparison
Compare NMCO & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- ABUS
- Stock Information
- Founded
- NMCO 2019
- ABUS N/A
- Country
- NMCO United States
- ABUS United States
- Employees
- NMCO N/A
- ABUS N/A
- Industry
- NMCO Finance/Investors Services
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- NMCO Finance
- ABUS Health Care
- Exchange
- NMCO Nasdaq
- ABUS Nasdaq
- Market Cap
- NMCO 598.4M
- ABUS 617.3M
- IPO Year
- NMCO N/A
- ABUS N/A
- Fundamental
- Price
- NMCO $10.68
- ABUS $3.49
- Analyst Decision
- NMCO
- ABUS Strong Buy
- Analyst Count
- NMCO 0
- ABUS 4
- Target Price
- NMCO N/A
- ABUS $5.50
- AVG Volume (30 Days)
- NMCO 207.6K
- ABUS 967.3K
- Earning Date
- NMCO 01-01-0001
- ABUS 03-27-2025
- Dividend Yield
- NMCO 5.43%
- ABUS N/A
- EPS Growth
- NMCO N/A
- ABUS N/A
- EPS
- NMCO N/A
- ABUS N/A
- Revenue
- NMCO N/A
- ABUS $6,171,000.00
- Revenue This Year
- NMCO N/A
- ABUS N/A
- Revenue Next Year
- NMCO N/A
- ABUS $61.99
- P/E Ratio
- NMCO N/A
- ABUS N/A
- Revenue Growth
- NMCO N/A
- ABUS N/A
- 52 Week Low
- NMCO $8.52
- ABUS $2.30
- 52 Week High
- NMCO $11.64
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- NMCO 34.75
- ABUS 58.08
- Support Level
- NMCO $10.62
- ABUS $3.20
- Resistance Level
- NMCO $11.08
- ABUS $3.45
- Average True Range (ATR)
- NMCO 0.12
- ABUS 0.15
- MACD
- NMCO -0.03
- ABUS 0.02
- Stochastic Oscillator
- NMCO 26.92
- ABUS 90.38
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.